Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656394 · ClinicalTrials.gov registry record · Phase 2
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
A Phase 2 study, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02656394: Completed Phase 2 study, sponsored by Glia.
NCT02656394 is a Phase 2 study that has completed, run by Glia. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02656394, a Phase 2 study, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.
Primary Outcome
Glaucoma medication ocular side effect symptoms: * Ocular discomfort * Burning * Stinging * Conjunctival redness * Itching * Dryness * Foreign object sensation * Grittiness * Pain * Eyelid swelling * Eyelid redness * Photophobia * Excessive tearing * Crusty lids * Blurred vision
Interventions
- DRUG Placebo
- DRUG GL101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-01-22 |
| Est. Completion | 2018-12-30 |
| Phase | Phase 2 |
What the finished NCT02656394 record still lists
NCT02656394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02656394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02656394 about?
NCT02656394 is a clinical study titled "Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101". To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.
What is the current status of trial NCT02656394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2016-01-22. Estimated completion is 2018-12-30.
What interventions are being tested in trial NCT02656394?
The interventions under investigation include: Placebo (DRUG), GL101 (DRUG).
Who is sponsoring clinical trial NCT02656394?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02656394's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI